Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Revenue by Major Customers by Reporting Segments

The following table summarizes revenues from each of the Company’s customers which individually accounted for 10% or more of its total net revenue:

	Three Months Ended March 31,
	2024		2023
Customer A	21	%	22	%
Customer B	15	%	14	%
Customer C	23	%	20	%
Customer D	10	%	9	%

Schedule of Disaggregated Revenue

The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for the three months ended March 31, 2024 and 2023, are set forth below (in thousands):

		Three Months Ended March 31,
		2024		2023
Generics
	Anti-infective	$	6,110	$	5,174
	Hormonal / allergy	107,714		104,851
	Antiviral	3,866		25,474
	Central nervous system	109,456		84,582
	Cardiovascular system	45,878		32,503
	Gastroenterology	18,197		14,364
	Oncology	38,533		10,578
	Metabolic disease / endocrine	11,185		9,265
	Respiratory	11,136		12,815
	Dermatology	18,975		18,004
	Other therapeutic classes	18,523		25,895
	International and other	1,721		301
	Total Generics net revenue	391,294		343,806
Specialty
	Hormonal / allergy	29,375		24,763
	Central nervous system	66,276		60,139
	License agreement (1)	4,479		—
	Other therapeutic classes	5,104		6,776
	Total Specialty net revenue	105,234		91,678
AvKARE
	Distribution	109,713		83,230
	Government label	34,952		24,516
	Institutional	10,858		8,862
	Other	7,140		5,448
	Total AvKARE net revenue	162,663		122,056
	Total net revenue	$	659,191	$	557,540

(1)Refer to Note 4. Alliance and Collaboration for information on revenue recognized under a license agreement.

Schedule of Major Categories of Sales-Related Deductions

A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2024 is as follows (in thousands):

	Contract Charge - Backs and Sales Volume Allowances		Cash Discount Allowances		Accrued Returns Allowance		Accrued Medicaid and Commercial Rebates
Balance at December 31, 2023	$	559,334	$	23,892	$	136,486	$	90,690
Provision related to sales recorded in the period	885,322		30,073		16,220		61,271
Credits/payments issued during the period	(987,202)		(26,550)		(15,598)		(55,250)
Balance at March 31, 2024	$	457,454	$	27,415	$	137,108	$	96,711